Navigation Links
The cocaine danger,,

Inhaling too much cocaine is well known to cause damage to arteries - but now a new study reveals that it can force the body to attack itself.New Scientist reports this week that the number of people admitted to US hospitals with cocaine related emergencies has jumped from around 80,000 in 1990 to nearly double that two years ago.//

Working on rabbit hearts, a University of Michigan team have found that taking in cocaine causes a reaction called a complement cascade. This occurs when there is a jump in the body's production of complement proteins. These proteins normally form in response to invading microorganisms, and build up on cell membranes causing them to break apart.

In a sense, the body is seeing the drug as a foreign body, or germ. When cocaine is introduced, the complement proteins build up on the body's own cells, causing massive tissue damage. Michael Davies of St George's Hospital said the research could explain why some cocaine users develop heart failure, where the heart becomes floppy and pumps blood less efficiently.

The chest pains which many cocaine users complain of is due to the drug sending coronary arteries into spasm, researchers say.Researchers say cocaine is now so widespread that cocaine users presenting with chest pains are beginning to drain hospital resources. One drug abuse expert at St Mary's Hospital in London said he suspected up to 10 per cent of people reporting to hospital with chest pains had used cocaine.


'"/>




Page: 1

Related medicine news :

1. Lack of treatment for cocaine users
2. Rising numbers indicate looming cocaine epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The cocaine danger

(Date:7/9/2008)...etic outcome after lumpectomy linked to depression...9 (HealthDay News) -- A third of women who opt for...e an asymmetry between their breasts that greatly ..., Women whose affected breast looked noticeably ...ar their cancer returning and to have symptoms of ...
(Date:7/9/2008)...ship Integrates In-Store and Online Marketing to C...erience, PITTSBURGH and NEW YORK, July 9 /PRNewsw..."GNC"), the largest global specialty retailer of,n...he leading source of,health information, today ann...ase consumer awareness and understanding of the im...
(Date:7/9/2008)...LAS and PLANO, Texas, July 9 /PRNewswire/ -- SKINT... is pleased to announce the arrival,of newly FDA-a...gen filler,in the Skintastic arsenal of little-or-...s immediate, predictable visible results, with lit...orted with EVOLENCE(R) in a,comparison study again...
(Date:7/9/2008)... DRE, Inc., a premier international...its customers that as much as $250,000 in medical ...me tax filings. , Louisvi...lus Act of 2008, in accordance with Tax Code Secti... equipment bought in 2008. This could make 2008 an...
Breaking Medicine News(10 mins):Health News:Breast-Conserving Surgery Leaves Many Cancer Patients Disappointed 2Health News:GNC and WebMD Announce Agreement To Provide Consumers with Health and Nutritional Information While Promoting the Benefits of a Healthy Lifestyle 2Health News:GNC and WebMD Announce Agreement To Provide Consumers with Health and Nutritional Information While Promoting the Benefits of a Healthy Lifestyle 3Health News:New Injectable Collagen Filler Offers Natural Results 2Health News:Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 2
...creased by 12% in six years, according to the char...are now diagnosed with the disease, 3,000 of those...elanomas in men is that they tend to occur more co...they are often on the lower leg and more noticeabl...
...nancy can increase a mother's risk of having a hyp...ere very anxious// in the last three months of pre.... Lead researcher Professor Vivette Glover, of Im... only applied to women who had extreme anxiety, an...
...n somebody is likely to have an epileptic seizure....enly and without warning and can lead to disabilit... la Pitie-Salpetriere, Paris, believe it may be po...res by carrying out an electroencephalogram (EEG)....
...than 100 years. And while most of the popular reme... the use of aspirin has increased. This powerful p...nt blood clots, and even reduce the risk of heart ...35 years since aspirin's potent anti-clotting effe...
Other Medicine News:
(Date:7/8/2008)...- McGraw-Hill Professional, a leading,global provi...d medical,communities, today announced the additio...its comprehensive online pharmacy education,resour... ). Through an alliance with,Doctor Evidence, deve...ical,studies, AccessPharmacy now provides in-conte...
(Date:7/7/2008)... Includes ANA598 and ANA773 Acting via In... Conference Call Today at 2:00 PM... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) ann...ation of the Toll-Like Receptor-7 (TLR7) mechanism...n preclinical pharmacology testing,and the results...
(Date:7/7/2008)...-- OrbusNeich today announced that data,presented ...e Society of,Interventional Cardiology demonstrate... outcomes when compared to drug-eluting stents., ...principal,investigator and a professor with the Fe...ology, Department of Clinical Medicine and Cardiov...
(Date:7/6/2008)...ing Authorization Application currently ...uly 7 /- Cell Therapeutics,...the publication of results from its,randomized pha...glumex,CT-2103) with gemcitabine or vinorelbine f...tients with previously untreated non-small cell,lu...
Breaking Medicine Technology:McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5APIC launches first national C difficile prevalence study 14826 1APIC launches first national C difficile prevalence study 14826 2Cato Study Finds Iran a Surprising Model for Kidney Markets 14823 1Cato Study Finds Iran a Surprising Model for Kidney Markets 14823 2NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 1573 1NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 1573 2Subterfuge counter surveillance and assassination 3A The bodys fight with cervical cancer 2560 1Subterfuge counter surveillance and assassination 3A The bodys fight with cervical cancer 2560 2
...007 - Affymax, Inc.,(Nasdaq:AFFY) today announced ... trials of Hematide(TM) in dialysis and,non-dialys... showed,that in treatment naive, non-dialysis pati...ed monthly at an appropriate dose.,Similarly, the ...three-times weekly Epoetin Alfa demonstrated that ...
...CytRx Corporation,(NASDAQ:CYTR) today announced th... exclusively licensed to its majority-owned,subsid...een,published in the April 2007 issue of peer-revi...technology was developed by RXi,Co-founder, Scient...chusetts Medical School (UMMS) Professor of Bioche...
Other Medicine Technology:Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 2Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: